Amyloidosis: open trials in Japan

12 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Intellia Therapeutics
Kumamoto University Hospital, Kumamoto · National Cerebral and Cardiovascular Center, Osaka · The University of Tokyo Hospital, Tokyo · Toyama University Hospital, Toyama
Registry updated 2026-11-04
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Japanese Red Cross Medical Center, Shibuya City · Osaka University Hospital, Suita-shi · The Cancer Institute Hospital of JFCR, Tokyo
Registry updated 2026-11-03
NCT07207811
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Trial Treatment · Phase 3 · Novo Nordisk A/S
Hyogo PrefecturalAmagasaki General Medical Center, Amagasaki · Nippon Medical School Hospital, Bunkyo-ku · Saiseikai Fukuoka General Hospital, Fukuoka · Hyogo Prefectural Harima-Himeji General Medical Center, Himeji · Kitasato University - Kitasato University Hospital (KUH), Kanagawa · Nara Medical University Hospital, Kashihara · Hospital of University of Occupational and Environmental Health, Kitakyushu · Kobe University Hospital, Kobe · Social Welfare Organization Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto · Kumamoto University Hospital, Kumamoto · Kurume University - Research Center for Innovative Cancer Therapy, Kurume-shi · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Shinshu University Hospital, Shinshu University Graduate School Of Medicine, Matsumoto · Nagasaki University Hospital, Nagasaki · Nagoya University Hospital, Nagoya · Kochi Medical School Hospital, Nankoku-shi · Osaka Metropolitan University Hospital, Osaka · Sapporo Medical University Hospital, Sapporo · National Cerebral and Cardiovascular Center, Suita · Keio University Hospital, Tokyo · Toyama Prefectural Central Hospital, Toyama · Mie University Graduate School of Medicine, Tsu · Uwajima City Hospital, Uwajima-shi · Yamaguchi University Hospital, Yamaguchi Prefecture · Showa University Fujigaoka Hospital, Yokohama
Registry updated 2026-10-21
NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Bunkyō City · Fukuoka · Kagawa · Kashihara · Kobe · Kumamoto · Kurume · Matsumoto-shi · Nagoya · Nankoku · Niigata · Okayama · Sapporo · Sendai · Suita · Tokyo
Registry updated 2026-10-20
NCT07358078
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Research · Alnylam Pharmaceuticals
Bunkyō City · Kumamoto · Kurume · Matsumoto · Sendai · Shinjuku · Suita · Tsukuba · Ube · Yufu
Registry updated 2026-10-09
NCT07223203
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Bunkyo C · Kumamoto · Matsumoto-shi · Suita
Registry updated 2026-10-08
NCT06355934
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Research · AstraZeneca
Tokyo
Registry updated 2026-09-09
NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Trial Treatment · Phase 3 · Eidos Therapeutics, a BridgeBio company
Kumamoto University Hospital, Kumamoto · Shinshu University Hospital, Nagano
Registry updated 2026-08-04
NCT06158854
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Trial Treatment · Phase 1/2 · AbbVie
Kumamoto University Hospital /ID# 262579, Kumamoto · Nagoya City University Hospital /ID# 256086, Nagoya · Japanese Red Cross Medical Center /ID# 256083, Shibuya-ku
Registry updated 2026-05-13
NCT05667493
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Ionis Pharmaceuticals, Inc.
Saiseikai Fukuoka General Hospital, Fukuoka · Hamamatsu University Hospital, Hamamatsu · Kumamoto University Hospital, Kumamoto · Kurume University Hospital, Kurume · Kurume University Hospital, Kurume-shi · Shinshu University Hospital, Matsumoto · Okayama University Hospital, Okayama · Osaka Metropolitan University Hospital, Osaka · Sapporo Medical University Hospital, Sapporo · Keio University Hospital, Shinjuku-ku
Registry updated 2026-04-17
NCT07306949
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
Trial Treatment · Phase 4 · Alexion Pharmaceuticals, Inc.
Bunkyō City · Kumamoto · Kurume-shi · Kyoto · Mitaka-shi · Nagoya · Nankoku-shi · Okayama · Ōtsu · Sagamihara-shi · Sapporo · Shinjuku-ku · Suita-shi · Tsu · Yufu-shi
Registry updated 2026-01-07
NCT06894290
International Cardiac Amyloidosis Registry
Research · Leiden University Medical Center
Kitasato University Hospital, Sagamihara
Registry updated 2025-03-25

All Amyloidosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error